Amarin Corp Plc (AMRN)

[TCI1]

Net revenue is up 49% Q2 2023 v 2022 yet prescriptions are up 91%. Wonder what the reason for this difference is? Distribution timing? Reduction in reimbursement price achieved with provinces versus private insurers (a lot of prior revenue was private insurers). They note slow uptake by GPs - Pfizer are responsible for this area if I remember correctly. Are their reps focused on other drugs. Who knows but revenue growth is disappointing.